Dystrophin expression following the transplantation of normal muscle precursor cells protects mdx muscle from contraction-induced damage

Cell Transplantation
J RousseauJacques P Tremblay

Abstract

Duchenne muscular dystrophy (DMD) is the most frequent muscular dystrophy. Currently, there is no cure for the disease. The transplantation of muscle precursor cells (MPCs) is one of the possible treatments, because it can restore the expression of dystrophin in DMD muscles. In this study, we investigated the effects of myoblasts injected with cardiotoxin on the contractile properties and resistance to eccentric contractions of transplanted and nontransplanted muscles. We used the extensor digitorum longus (EDL) as a model for our study. We conclude that the sole presence of dystrophin in a high percentage of muscle fibers is not sufficient by itself to increase the absolute or the specific force in the EDL of transplanted mdx muscle. This lack of strength increase may be due to the extensive damage that was produced by the cardiotoxin, which was coinjected with the myoblasts. However, the dystrophin presence is sufficient to protect muscle from eccentric damage as indicated by the force drop results.

References

Jul 1, 1988·Neuron·E P HoffmanL M Kunkel
Sep 28, 1995·The New England Journal of Medicine·J R MendellR Rice
Aug 1, 1993·Journal of Muscle Research and Cell Motility·P MoensG Maréchal
Mar 1, 1997·Neuromuscular Disorders : NMD·A IrintchevA Wernig
Feb 3, 1998·Neuromuscular Disorders : NMD·V BrusseeJ P Tremblay
Oct 1, 1998·Biochemical and Biophysical Research Communications·V BrusseeJ P Tremblay
Feb 24, 1999·Sports Medicine·G L WarrenR B Armstrong
Feb 19, 2000·Microscopy Research and Technique·D Skuk, J P Tremblay
Apr 1, 2000·Journal of Neuropathology and Experimental Neurology·D SkukJ P Tremblay
Apr 4, 2002·The Journal of the American Academy of Orthopaedic Surgeons·Michael Sussman
Apr 20, 2002·Journal of Muscle Research and Cell Motility·C DellorussoS V Brooks
Aug 2, 2002·Clinical Orthopaedics and Related Research·W Douglas BiggarPeter N Ray
Dec 2, 2004·Expert Opinion on Biological Therapy·Daniel Skuk
Jan 26, 2005·Molecular Therapy : the Journal of the American Society of Gene Therapy·Mingju LiuDongsheng Duan
Jun 15, 2007·American Journal of Physiology. Cell Physiology·S ChanJ W Morley
Jun 5, 2008·Cell Transplantation·Basma F BenabdallahJacques P Tremblay
Jan 22, 2009·Archives of Physical Medicine and Rehabilitation·Fabrisia AmbrosioJohnny Huard

❮ Previous
Next ❯

Citations

Mar 8, 2012·Journal of Tissue Engineering and Regenerative Medicine·Xiaorong MaFang Chen
Oct 13, 2011·The Journal of Pathology·Virginie Carmignac, Madeleine Durbeej
Jul 5, 2012·Journal of Tissue Engineering and Regenerative Medicine·Tobias WinklerCarsten Perka
Aug 5, 2010·Molecular Therapy : the Journal of the American Society of Gene Therapy·Sébastien GoudenegeJacques P Tremblay
May 4, 2011·Cell Transplantation·Raouia FakhfakhJacques P Tremblay
Oct 26, 2010·Journal of Muscle Research and Cell Motility·Ian Curtis SmithRene Vandenboom
Oct 18, 2011·Current Opinion in Organ Transplantation·Jean-Thomas VilquinKarine Vauchez

❮ Previous
Next ❯

Methods Mentioned

BETA
force measurements

Software Mentioned

LabView
SAS

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.